Expert Opinion on Pharmacotherapy

Current best treatment for non-alcoholic fatty liver disease
pp. 611-623(13)
Author: Angulo P.

Current pharmacotherapy in the management of cirrhosis: focus on the hyperdynamic circulation
pp. 625-637(13)
Authors: Vaughan R.B.; Chin-Dusting J.P.

Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures
pp. 639-652(14)
Authors: Mintz E.P.; Gruberg L.

Direct thrombin inhibitors
pp. 653-666(14)
Author: Kaplan K.L.

Effect of hormone replacement therapy on cardiovascular disease: current opinion
pp. 667-674(8)
Authors: Khan N.S.; Malhotra S.

Sex differences in heart disease incidence and prevalence: implications for intervention
pp. 675-683(9)
Authors: Witt B.J.; Roger V.L.

Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus
pp. 685-691(7)
Author: Foster G.R.

Best pharmacological practice: urinary tract infections
pp. 693-704(12)
Author: Nicolle L.

Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease
pp. 705-716(12)
Author: Dawson N.A.

Pharmacotherapy of first-episode psychosis
pp. 717-750(34)
Authors: Lambert M.; Conus P.; Lambert T.; McGorry P.D.

Atypical antipsychotics in the treatment of bipolar disorder
pp. 751-760(10)
Authors: Strakowski S.M.; Del Bello M.P.; Adler C.M.; Keck Jr P.E.

Paediatric community-acquired pneumonia: current concept in pharmacological control
pp. 761-777(17)
Authors: Principi N.; Esposito S.

Colesevelam HCl: a non-systemic lipidaltering drug
pp. 779-790(12)
Authors: Bays H.; Dujovne C.

Safety and efficacy of tenecteplase in acute myocardial infarction
pp. 791-798(8)
Authors: Guerra D.R.; Karha J.; Gibson C.M.

Zanamivir in the treatment of influenza
pp. 799-805(7)
Author: Fleming D.M.

Caspofungin: first approved agent in a new class of antifungals
pp. 807-823(17)
Authors: Johnson M.D.; Perfect J.R.

ACE inhibitors versus diuretics: ALLHAT versus ANBP2
pp. 825-828(4)
Author: Doggrell S.A.